Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bayer AG
Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl
Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.
Industry Supports Transparency On Proposed CMS Prior Authorization Rule
Industry trade groups applaud CMS’s proposal to increase transparency for prior authorization approvals but are asking for expedited timeframes to provide care.
- In Vitro Diagnostics
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
- Artificial Intelligence
- Other Names / Subsidiaries
- Actus Therapeutics, Inc.
- Asklepios BioPharmaceutical, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- Algeta ASA
- Bayer CropScience AG
- Bayer Consumer Care AG
- Berlex Laboratories
- BlueRock Therapeutics
- Conceptus Inc.
- Dihon Pharmaceutical Group Co., Ltd.
- Intendis GmbH
- Medrad Inc.
- Possis Medical
- Schering AG
- Monsanto Company
- Zeptosens AG
- KaNDy Therapeutics
- Vividion Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.